Riddle Mc Hart J. Hyperglycemia Recognised And Unrecognised As A Risk Factor For Stroke And Transient Ischemic Attacks. Stroke 1982 13 356-9. 7 Kane Wc Aronson Sm

The Big Diabetes Lie

Diabetes Solution at Home

Get Instant Access

Adams HP, Bendixen B, Kapelle J etal. (1993). Classification of subtypes of acute ischaemic stroke. Stroke 24: 35-41.

Adler A, Stratton IM, Neil HAW, Yudkin JS, Matthews DR, Cull CA etal. (2000). Association of systolic blood pressure with macrovascular and microvascular complications of type-2 diabetes (UKPDS 36): prospective observational study. British Medical Journal 321: 412-9.

Albers GW, Caplan LR, Easton JD, Fayad PB, Mohr JP, Saver JL, Sherman DG for the TIA Working Group (2002). Transient ischaemic attack - proposal for a new definition. New England Journal of Medicine 347: 1713-6.

Alex M, Baron EK, Goldenberg S, Blumenthal HT (1962). An autopsy study of cerebrovascular accident in diabetes mellitus. Circulation 25: 663-73.

Allport L, Butcher K, Baird T etal. (2004). Insular cortical ischemia is independently associated with acute stress hyperglycemia. Stroke 35: 1886-91.

Antiplatelet Trialists' Collaboration (1994). Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. British Medical Journal 308: 81-106.

Areosa Sastre A, Grimley Evans J (2003). Effect of the treatment of type II diabetes mellitus on the development of cognitive impairment and dementia (Cochrane Review). The Cochrane Library, Issue 4. Oxford: Oxford Update Software.

Astrup J, Symon L, Branston NM etal. (1977). Cortical evoked potential and extracellular K+ and H+ at critical levels of brain ischemia. Stroke 8: 51-7.

Astrup J, Siesjo BK, Symon L (1981). Thresholds in cerebral ischemia - the ischemic penumbra. Stroke 12: 723-5.

Baird TA, Parsons MW, Phanh T etal. (2003). Persistent poststroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome. Stroke 34: 2208-14.

Bamford J, Sandercock P, Dennis M, Burn J, Warlow C (1991). Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 337: 1521-6.

Barba R, Martinez-Espinosa S, Rodriguez-Garcia E, Podal M, Vivancos J, Del Ser T (2000). Poststroke dementia: clinical features and risk factors. Stroke 31: 1494-501.

Beghi E, Boglium G, Cavaleth G, Sanguinetti I, Agliabue M, Agostoni F, Macchi I (1989). Haemorrhagic infarction, risk factors, clinical and tomographic features and outcome. A case control study. Acta Neurologica Scandinavica 80: 226-31.

Berthet K, Neal BC, Chalmers JP, etal. (2004). Reductions in the risks of recurrent stroke in patients with and without diabetes: the PROGRESS Trial. Blood Pressure 13: 1-7.

Blood Pressure Lowering Treatment Trialists' Collaboration (2000). Effects of ACE inhibitors, calcium antagonists and other blood pressure lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 356: 1955-64.

Bosch J, Yusuf S, Pogue J etal. (2002). Use of Ramipril in preventing stroke: double blind randomised trial. British Medical Journal 324: 799-802.

Brown RD, Whisnant JP, Sicks JD, O'Fallon WM, Weibers DO (1996). Stroke incidence, prevalence and survival: secular trends in Rochester, Minnesota, through 1989. Stroke 27: 373-80.

Bruno A, Levine SR, Frankel MR, Brott TG, In Y, Tilley BC, Lyden PD, Broderick JP, Kwaitowski TG, Fineberg SE for the NINDS rt-PA Stroke Study Group (2002). Admission glucose levels and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology 59: 669-74.

Bucher HC, Griffith LE, Guyatt GH (1998). Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomised controlled trials. Annals of Internal Medicine 128: 89-95.

Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein GH (2001). Stress hyperglycaemia and prognosis of stroke in nondiabetic and diabetic patients. Stroke 32: 2426-32.

Carolei A and Marini C (2000). Surgical and medical therapy in asymptomatic carotid lesions. In: Fieschi C, Fisher M (eds) Prevention of Ischaemic Stroke. London: Martin Dunitz, pp. 217-230.

Coutinho M, Wang Y, Gerstein HC, Yusuf S (1999). The relationship between glucose and incident cardiovascular events. Diabetes Care 22: 233-40.

Dahlof B, Lindholm LH, Hansson L etal. (1991). Morbidity and mortality in the Swedish trial in old Patients with Hypertension (STOP-Hypertension). Lancet 338: 1281-5.

De Angelis M (2003). Prevalence of carotid stenosis in type 2 diabetic patients asymptomatic for cerebrovascular disease. Diabetes Nutrition and Metabolism 16: 48-55.

Demchuk AM, Morgenstern LB, Krieger DW, Chi TL, Hu W, Wein TH, Hardy RJ, Grotta JC, Buchan AM (1999). Serum glucose level and diabetes predict tissue plasminogen activator related intracerebral haemorrhage in acute ischemic stroke. Stroke 30: 34-9.

Diaz R, Ernesto A, Paolasso A, etal. (1998). Metabolic modulation of acute myocardial infarction. The ECLA Glucose Insulin-Potassium Pilot Trial. Circulation 98: 2227-34.

Diener H-C, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht H-J on behalf of the MATCH Investigators (2004). Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo controlled trial. Lancet 364: 331-7.

Eastern Stroke and Coronary Heart Disease Collaborative Research Group (1998). Blood pressure, cholesterol and stroke in eastern Asia. Lancet 352: 1801-7.

European Carotid Surgery Trialists' Collaborative Group (1991). MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. Lancet 337: 1235-43.

European Carotid Surgery Trialists' Collaborative Group (1998). Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECSt). Lancet 351: 1379-87.

Fath-Ordoubadi F, Beatt KJ (1997). Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomised placebo controlled trials. Circulation 96: 1152-6.

Fuller JH, Shipley MJ, Rose G, Jarret RJ, Keen M (1983). Mortality from coronary heart disease and stroke in relation to degree of glycaemia: The Whitehall Study. British Medical Journal 287: 867-70.

Gaede P, Vedel P, Larson N, Jenson GVH, Parving H-H, Pedersen O (2003). Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New England Journal of Medicine 348: 383-93.

Ginsberg MP, Reivich M, Giandomenico A, Greenberg JH (1977). Local glucose utilization in acute local cerebral ischemia: local dysmetabolism and diaschisis. Neurology 27: 1042-8.

Gray CS, Taylor R, French JM etal. (1987). The prognostic value of stress hyperglycaemia and previously unrecognised diabetes following acute stroke. Diabetic Medicine 4 : 237-40.

Gray CS, Taylor R, French JM etal. (1992). The prognostic value of stress hyperglycaemia and previously unrecognised diabetes mellitus in acute stroke. Journal of Neurology, Neurosurgery, and Psychiatry 55: 263-70.

Gray CS, O'Connell JE, Lloyd H (2001). Diabetes, hyperglycaemia and recovery from stroke. Geriatrics and Gerontology International 1: 2-7.

Gray CS, Scott JF, French JM, Alberti KGMM, O'Connell JE (2004a). Prevalence and prediction of unrecognised diabetes mellitus and impaired glucose tolerance following acute stroke. Age and Ageing 33: 71-7.

Gray CS, Hildreth AJ, Alberti KGMM, O'Connell JE on behalf of the GIST Collaboration (2004b). Post stroke hyperglycemia; natural history and immediate management. Stroke 35: 122-6.

Gubitz G, Phillips S, Dwyer V (1999). What is the cost of admitting patients with transient ischaemic attack to hospital? Cerebrovascular Diseases 9: 210-4.

Haan MN, Mungas DM, Gonzalez HM, Ortiz TA, Acharya A, Jagust WJ (2003). Prevalence of dementia in older Latinos: the influence of type 2 diabetes mellitus, stroke and genetic factors. Journal of the American Geriatrics Society 51: 169-77.

Hankey GJ (1996). Impact of treatment of people with transient ischaemic attacks on stroke incidence and public health. Cerebrovascular Diseases 6 (Suppl 1): 26-33.

Hansson L, Zanchetti A, Carruthers SG etal. (1998). Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal treatment (HOT) randomised trial. Lancet 351: 1755-62.

Heart Outcomes Prevention Evaluation (HOPE) Study Investigators (2000). Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355: 253-9.

Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. New England Journal of Medicine 342: 145-53.

Heart Protection Study Collaborative Group (2002). MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo controlled trial. Lancet 360: 7-22.

Heart Protection Study Collaborative Group (2003). MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361: 2005-16.

den Heiger T, Vermeer SE, Van Dijk EJ etal. (2003). Type 2 diabetes mellitus and atrophy of medial temporal lobe structures on brain MRI. Diabetologia 46: 1604-10.

Hess DC, Demchuk AM, Brass LM, Yatsu FM (2000). HMG-CoA reductase inhibitors (statins). A promising approach to stroke prevention. Neurology 54: 790-6.

Honig LS, Tang M-X, Albert S etal. (2003). Stroke and the risk of Alzheimer disease. Archives of Neurology 60: 1707-12.

INDANA Project Collaborators (1997). Effect of antihypertensive treatment in patients already having suffered from stroke. Gathering the evidence. Stroke 28: 2557-62.

Intercollegiate Working Party for Stroke (2000). National Clinical Guidelines for Stroke. London: Royal College of Physicians.

Isarol PA, Forbes JF (1992). The cost of stroke to the National Health Service in Scotland. Cerebrovascular Diseases 1: 47-50.

Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD for the MRFIT Research Group (1989). Serum cholesterol levels and six year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial. New England Journal of Medicine 320: 904-10.

Johnston SC, Gress DR, Browner WS, Sidney S (2000a). Short tem prognosis after emergency department diagnosis of TIA. Journal of the American Medical Association 284: 2901-6.

Johnston SC, Fung LH, Gillum LA etal. (2000b). Utilisation of intravenous tissue-type plasminogen activator for ischaemic stroke: the Cleveland Area Experience. Journal of the American Medical Association 283: 1151-8.

Kannel WB, McGee DL (1979). Diabetes and cerebrovascular disease. The Framingham Study. Journal of the American Medical Association 241: 2035-8.

Kiers L, Davis SM, Larkins R etal. (1992). Stroke topography and outcome in relation to hyperglycaemia and diabetes. Journal of Neurology, Neurosurgery, and Psychiatry 55: 263-70.

Laing SP, Swerdlow AJ, Carpenter LM, Slater SD, Burden AC, Botha JL, Morris AD, Waugh NR, Gatling W, Gale EAM, Patterson CC, Zongkai Q, Keen H (2003). Mortality from cerebrovascular disease in a cohort of 23000 patients with insulin-treated diabetes. Stroke 34: 418-21.

MacDonald BK, Cockerell OC, Sander JWAS, Shorvon SD (2000). The incidence and lifetime prevalence of neurological disorders in a prospective community based study in the UK. Brain 123: 665-75.

Malmberg K, Ryden L, Efendic S etal. (1995). Randomised trial of insulin glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): Effects on mortality at one year. Journal ofthe American College of Cardiology 26: 57-65.

Megherbi SE, Milan C, Couvreur G, Osseby GV, Tilling K, di Carlo A, Inzitari D, Wolf CD, Moreau T, Giroud M; European BIOMED Study of Stroke Care Group (2003). Association between diabetes and stroke subtype on survival and functional outcome 3 months after stroke: data form the European BIOMED Stroke Project Stroke 34: 688-94.

Munch G, Schinzel R, Loske C etal. (1998). Alzheimer's disease - synergistic effects of glucose deficits, oxidative stress and advanced glycosylation end products. Journal of Neural Transmission 105: 439-61.

Norris JW, Zhu CZ, Bornstein NM, Chambers BR (1991). Vascular risks of asymptomatic carotid stenosis. Stroke 22: 1485-90.

O'Connell JE, Gray CS (1994). Treating hypertension after stroke British Medical Journal 308: 1523-4.

Ohkubo Y, Kishikawa H, Araki E etal. (1995). Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependant diabetes mellitus: a randomised prospective study. Diabetes Research and Clinical Practice 28: 103-17.

Olsson T, Viitanen M, Asplund K, Eriksson S, Hagg E (1990). Prognosis after stroke in diabetic patients. A controlled prospective study. Diabetologia 33: 244-9.

O'Neill PA, Davis I, Fullerton KJ, Bennett D (1991). Stress hormone and blood glucose response following acute stroke in the elderly. Stroke 22: 842-7.

Oppenheimer SM, Hoffbrand B, Oswald GA, Yudkin JS (1985). Diabetes mellitus and early mortality from stroke. British Medical Journal 291: 1014-5.

Park HL, O'Connell JE, Thomson RG (2003). A systematic review of cognitive decline in the general elderly population. International Journal of Geriatric Psychiatry 18: 1121-34.

Peila R, Rodriguez BL, Launer LJ (2002). Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging study. Diabetes 51: 1256-62.

Peress NS, Kane WC, Aronson SM (1972). Central nervous system findings in a tenth decade autopsy population. Progress in Brain Research 40: 473-83.

Power MJ, Fullerton KJ, Stout RW (1988). Blood glucose and prognosis of acute stroke. Age and Ageing 17: 164-70.

PROGRESS Collaborative Group (2001). Randomised trial of a perindopril-based blood pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 358: 1033-41.

Prospective Studies Collaboration (1995). Cholesterol, diastolic blood pressure and stroke. 13000 strokes in 450,000 people in 45 prospective cohorts. Lancet 346: 1647-53.

Pulsinelli WA (1992). Pathophysiology of acute stroke. Lancet 339: 533-6.

Pulsinelli WA, Levy DE, Sigsbee B, Scherer P, Plum F (1983). Increased damage after ischaemic stroke in patients with hyperglycaemia with or without established diabetes mellitus. American Journal of Medicine 74: 540-3.

Pulsinelli WA, Kraig RP, Plum F (1985). Hyperglycaemia, cerebral acidosis and ischaemic brain damage. In: Plum F, Pulsinelli WA (eds) Cerebrovascular Diseases 14th Princeton Conference. New York: Raven Press, pp. 201-10.

Reichard P, Berglund B, Britz A, Cars I, Nilsson BY, Rosenqvist U (1991). Intensified conventional insulin treatment retards the microvascular complications of insulin dependant diabetes mellitus (IDDM): the Stockholm Diabetes International Study (SDIS) after 5 years. Journal of Internal Medicine 230: 101-8.

Riddle MC, Hart J (1982). Hyperglycemia, recognised and unrecognised, as a risk factor for stroke and transient ischemic attacks. Stroke 13: 356-9.

Robinson TG, Potter JF (2004). Blood pressure in acute stroke. Age and Ageing 33: 6-12.

Rodgers A, McMahon S, Gamble G etal. on behalf of the United Kingdom Transient Ischaemic Attack Collaborative Group (1996). Blood pressure and risk of stroke in patients with cerebrovascular disease. British Medical Journal 313: 147.

Roman GC (2003). Vascular dementia: distinguishing characteristics, treatment and prevention. Journal of the American Geriatrics Society 51: S296-304.

Scott JF, Robinson G, O'Connell JE, Alberti KGMM, Gray CS (1999). Prevalence of admission hyperglycaemia across clinical sub types of acute stroke. Lancet 353: 376-7.

SHEP Co-operative Research Group (1991). Prevention of stroke by hypertensive drug therapy in older persons with isolated systolic hypertension: final results of the systolic hypertension in the elderly programme. Journal of the American Medical Association 265: 3255-64.

Siemkowicz E, Hanson AJ (1978). Clinical restitution following cerebral ischaemia in hypo-, normo- and hyperglycaemic rats. Acta Neurologica Scandinavica 58: 1-8.

Song EC, Chu K, Jeong SW et al. (2003). Hyperglycemia exacerbates brain edema and perihematomal cell death after intracerebral hemorrhage. Stroke 34: 2215-20.

Stamler J, Vaccaro O, Neaton JD, Wentworth D (1993). Diabetes, other risk factors and 12 year cardiovascular mortality for men screened in Multiple Risk Factor Intervention Trial. Diabetes Care 16: 434-44.

Stroke Unit Trialists' Collaboration (1997). Collaborative systematic review of the randomised trials of organised in patient (stroke unit) care after stroke. British Medical Journal 314: 1151-9.

Svensson P, de Faire U, Sleight P, Ostergren J (2001). Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension 38: e28-32.

Thomas T, Thomas G, McLendon C, Sutton T, Mullan M (1996). ß Amyloid mediated vasoactivity and vascular endothelial damage. Nature 380: 168-71.

Toni D, Fiorelli M, Gentile M etal. (1995). Deteriorating neurological deficit secondary to acute ischaemic stroke: a study on predictability, pathogenesis and prognosis. Archives of Neurology 52: 670-5.

UK Prospective Diabetes Study Group (1996). UK Prospective Diabetes Study 17: a nine year update of a randomised controlled trial on the effect of improved metabolic control on complications in non insulin dependant diabetes mellitus. Annals of Internal Medicine 124: 136-45.

UK Prospective Diabetes Study Group (1998). Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). British Medical Journal 317: 703-13.

UK Prospective Diabetes Study (UKPDS) Group (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-53.

Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R (2001). Intensive insulin therapy in critically ill patients. New England Journal of Medicine 345: 1359-67.

Vázquez-Cruz J, Martí-Vilalta JL, Ferrer I, Pérez-Gallofré A, Folch J (1990). Progressing cerebral infarction in relation to plasma glucose in gerbils. Stroke 21: 1621-4.

Wahl PW, Savage PJ, Psaty BM, Orchard TJ, Robbins JA, Tracy RP (1998). Diabetes in older adults: comparison of 1997 American diabetes Association classification of diabetes mellitus with 1985 WHO classification. Lancet 352: 1012-5.

Wardlaw J, Yamaguchi T, Del Zoppo G (2002). Thrombolysis for acute ischaemic stroke (Cochrane Review). The Cochrane Library, Issue 2. Oxford: Oxford Update Software.

Warlow CP, Dennis MS, van Gijn J, Sandercock PAG, Bamford JM, Wardlaw JM (2001). Preventing recurrent stroke and other serious vascular events. In: Warlow CP, Dennis MS, van Gijn J, Sandercock PAG, Bamford JM, Wardlaw JM (eds) Stroke: a Practical Guide to Management. Oxford: Blackwell Science, pp. 653-722.

Weir CJ, Murray GD, Dyker AG, Lees KR (1997). Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long term follow up study. British Medical Journal 314: 1303-6.

Williams B, Poulter NR, Brown MJ etal. (2004). Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004 - BHS IV. Journal of Human Hypertension 18: 139-85.

Wolf PA, Kannel WB, Verter J (1983). Current status of risk factors for stroke. Neurologic Clinics 1: 330-1.

Woo E, Ma JTC, Robinson JD, Yu YL (1988). Hyperglycemia is a stress response in acute stroke. Stroke 19: 1359-64.

Yano K, Reed DM, MacLean CJ (1989). Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. Stroke 20: 1460-5.

Was this article helpful?

0 0
Unraveling Alzheimers Disease

Unraveling Alzheimers Disease

I leave absolutely nothing out! Everything that I learned about Alzheimer’s I share with you. This is the most comprehensive report on Alzheimer’s you will ever read. No stone is left unturned in this comprehensive report.

Get My Free Ebook

Post a comment